X0508 4 2025-12-10 0001683553 SPRUCE BIOSCIENCES, INC. SPRB 0001903669 Szwarcberg Javier B. C/O SPRUCE BIOSCIENCES, INC. 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO CA 94080 true true false false CHIEF EXECUTIVE OFFICER 0 Common Stock 2025-12-10 4 M 0 1196 0 A 10670 D Common Stock 2025-12-10 4 F 0 428 85.67 D 10242 D Common Stock 2025-12-11 4 M 0 4950 0 A 15192 D Common Stock 2025-12-11 4 F 0 2194 88.41 D 12998 D Restricted Stock Units 0 2025-12-10 4 M 0 1196 0 D Common Stock 1196 3588 D Restricted Stock Units 0 2025-12-11 4 A 0 19800 0 A Common Stock 19800 19800 D Restricted Stock Units 0 2025-12-11 4 M 0 4950 0 D Common Stock 4950 14850 D On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. Each RSU represents a contingent right to receive one share of SPRB common stock. 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. /s/ Samir Gharib, Attorney-in-Fact 2025-12-12